Cybin (HELP) Total Current Liabilities (2021 - 2026)
Cybin's (HELP) quarterly Total Current Liabilities came in at $19.4 million in Q1 2026, up 29.82% YoY from $14.9 million in Q1 2025, and up 19.77% on a QoQ basis from $16.2 million in Q4 2025.
Cybin (HELP) Total Current Liabilities (2021 - 2026) Analysis & Trends
Cybin (HELP) has 6 years of Total Current Liabilities data on file, last reported at $19.4 million in Q1 2026.
- Quarterly Total Current Liabilities rose 29.82% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (up 29.82% YoY) and the FY2026 annual result came in at $19.4 million, up 30.05% from the prior year.
- Total Current Liabilities climbed to $19.4 million in Q1 2026, from $16.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $19.4 million in Q1 2026 to a low of $3.2 million in Q4 2022.
- A 5-year average of $9.9 million and a median of $7.5 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities tumbled 33.11% — and 2025, when it surged 99.22%.
- Tracing HELP's Total Current Liabilities over 5 years: stood at $3.2 million in 2022, then jumped by 93.09% to $6.2 million in 2023, then rose by 20.55% to $7.5 million in 2024, then soared by 115.93% to $16.2 million in 2025, then climbed by 19.77% to $19.4 million in 2026.
- The last three Total Current Liabilities figures came in at $19.4 million (Q1 2026), $16.2 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | 19.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.38 Mn |
| Dec 31, 2025 | 16.18 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Jun 30, 2025 | 14.55 Mn |
| Mar 31, 2025 | 14.93 Mn |
| Mar 31, 2024 | 7.49 Mn |
| Dec 31, 2023 | 6.21 Mn |
| Jun 30, 2023 | 6.70 Mn |
| Feb 28, 2023 | 3.34 Mn |
| Dec 31, 2022 | 3.22 Mn |
| Sep 30, 2022 | 3.74 Mn |
| Dec 31, 2021 | 4.81 Mn |
| Sep 30, 2021 | 4.53 Mn |
| Jun 30, 2021 | 4.72 Mn |
| Mar 31, 2021 | 3.87 Mn |